MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity ...

In the European Union (EU) Member States, QDENGA is indicated for the prevention of dengue disease in individuals from four years of age and should be administered subcutaneously as a 0.5 mL dose at a ...

Discover Rhythm Pharmaceuticals’ Q3 2025 earnings insights, IMCIVREE launch updates, regulatory milestones, and global growth plans.

Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, ...

As cyber-threats evolve, so must our mindset. In his recent article at SC Media, Jim Routh (an esteemed Institute for ...

The biopharmaceutical firm Viking Therapeutics approaches a critical juncture as it prepares to unveil new clinical findings for its obesity treatment candidate, VK2735. These highly anticipated ...

Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced the publication online of Part 1 results from ...

Lp (a) data underscore importance of early detection of this independent CVD risk factor in premature ASCVD patients and potential benefit of Lp (a)-targeted therapies ...